MA30351B1 - Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation - Google Patents
Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisationInfo
- Publication number
- MA30351B1 MA30351B1 MA31320A MA31320A MA30351B1 MA 30351 B1 MA30351 B1 MA 30351B1 MA 31320 A MA31320 A MA 31320A MA 31320 A MA31320 A MA 31320A MA 30351 B1 MA30351 B1 MA 30351B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- methods
- tetrahydropyridothienopyrimidine
- pharmaceutical compositions
- variables
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne un composé de la Formule (I), Dans laquelle les variables sont telles que divulgué dans le mémoire descriptif, des compositions pharmaceutiques contenant lesdits composés, des procédés de fabrication des composés et des compositions pharmaceutiques et des procédés d'utilisation des composés et des compositions pharmaceutiques pour le traitement ou la prévention d'affections, en particulier du cancer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78414606P | 2006-03-20 | 2006-03-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA30351B1 true MA30351B1 (fr) | 2009-04-01 |
Family
ID=38523058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA31320A MA30351B1 (fr) | 2006-03-20 | 2008-10-20 | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US8501755B2 (fr) |
| EP (1) | EP2001890B1 (fr) |
| JP (1) | JP5282026B2 (fr) |
| KR (1) | KR20080110834A (fr) |
| CN (1) | CN101448840B (fr) |
| AR (1) | AR059901A1 (fr) |
| AT (1) | ATE495179T1 (fr) |
| AU (1) | AU2007227317A1 (fr) |
| BR (1) | BRPI0711045A2 (fr) |
| CA (1) | CA2647036C (fr) |
| CR (1) | CR10304A (fr) |
| DE (1) | DE602007011906D1 (fr) |
| DO (1) | DOP2007000053A (fr) |
| EC (1) | ECSP088749A (fr) |
| ES (1) | ES2357654T3 (fr) |
| GT (1) | GT200800187A (fr) |
| IL (1) | IL194028A0 (fr) |
| MA (1) | MA30351B1 (fr) |
| MX (1) | MX2008012006A (fr) |
| NZ (1) | NZ571326A (fr) |
| PA (1) | PA8719401A1 (fr) |
| PE (1) | PE20080144A1 (fr) |
| RU (1) | RU2008141239A (fr) |
| SV (1) | SV2008003032A (fr) |
| TN (1) | TNSN08370A1 (fr) |
| TW (1) | TW200804397A (fr) |
| UY (1) | UY30220A1 (fr) |
| WO (1) | WO2007109279A2 (fr) |
| ZA (1) | ZA200808017B (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| CA2699349C (fr) * | 2007-09-14 | 2016-04-19 | Bayer Schering Pharma Aktiengesellschaft | Composes heterocycliques tricycliques substitues utilises comme inhibiteurs egfr |
| US8507502B2 (en) | 2008-11-10 | 2013-08-13 | National Health Research Institutes | Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors |
| AU2013202373B2 (en) * | 2012-01-25 | 2016-04-14 | Proteostasis Therapeutics, Inc. | Proteasome activity enhancing compounds |
| JP2017519737A (ja) * | 2014-05-26 | 2017-07-20 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換テトラヒドロピリドチエノピリミジン |
| EP3111960B1 (fr) * | 2015-07-03 | 2019-12-11 | Kyoto University | Agent d'imagerie de diagnostic de médecine nucléaire |
| BR112018003417B1 (pt) | 2016-06-22 | 2023-10-24 | Vanderbilt University | Composto modulador alostérico positivo do receptor muscarínico de acetilcolina m4 e composição farmacêutica que o compreende |
| EP3544961B1 (fr) | 2016-11-07 | 2021-08-18 | Vanderbilt University | Modulateurs allostériques positifs du récepteur muscarinique de l'acétylcholine m4 |
| US10961253B2 (en) | 2016-11-07 | 2021-03-30 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| WO2018085803A1 (fr) | 2016-11-07 | 2018-05-11 | Vanderbilt University | Modulateurs allostériques positifs du récepteur muscarinique à l'acétylcholine m4 |
| US11376254B2 (en) | 2017-12-05 | 2022-07-05 | Vanderbilt University | Positive allosteric modulators of the muscarinic acetylcholine receptor M4 |
| TW201930311A (zh) | 2017-12-05 | 2019-08-01 | 泛德比爾特大學 | 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑 |
| US12398151B2 (en) | 2019-03-19 | 2025-08-26 | Suvalent Therapeutics, Inc. | Sumo inhibitor compounds and uses thereof |
| US20240391931A1 (en) * | 2021-08-05 | 2024-11-28 | Bristol-Myers Squibb Company | Tricyclic fused pyrimidine compounds for use as her2 inhibitors |
| CN114736154B (zh) * | 2022-03-15 | 2023-07-21 | 安庆朗坤药业有限公司 | N-（3-氯-4-（2-吡啶甲氧基）苯基）-2-氰基乙酰胺的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1346358A (zh) * | 1999-03-30 | 2002-04-24 | 日本曹达株式会社 | 噻吩并嘧啶化合物及其盐和制备方法 |
| DE19944604A1 (de) | 1999-09-17 | 2001-03-22 | Merck Patent Gmbh | Aminderivate |
| US6608053B2 (en) * | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| JPWO2003035653A1 (ja) * | 2001-10-26 | 2005-02-10 | 日本曹達株式会社 | ピリドチエノピリミジン化合物およびその塩 |
| ES2280040T3 (es) * | 2003-07-24 | 2007-09-01 | Bayer Pharmaceuticals Corporation | Compuestos de tetrahidrobenzotienopirimidinamina sustituidos utiles para tratar trastornos hiperproliferativos. |
-
2007
- 2007-03-15 AR ARP070101057A patent/AR059901A1/es not_active Application Discontinuation
- 2007-03-19 TW TW096109309A patent/TW200804397A/zh unknown
- 2007-03-19 UY UY30220A patent/UY30220A1/es not_active Application Discontinuation
- 2007-03-19 PE PE2007000292A patent/PE20080144A1/es not_active Application Discontinuation
- 2007-03-20 AT AT07753547T patent/ATE495179T1/de not_active IP Right Cessation
- 2007-03-20 WO PCT/US2007/006927 patent/WO2007109279A2/fr not_active Ceased
- 2007-03-20 DO DO2007000053A patent/DOP2007000053A/es unknown
- 2007-03-20 CA CA2647036A patent/CA2647036C/fr not_active Expired - Fee Related
- 2007-03-20 AU AU2007227317A patent/AU2007227317A1/en not_active Abandoned
- 2007-03-20 MX MX2008012006A patent/MX2008012006A/es active IP Right Grant
- 2007-03-20 PA PA20078719401A patent/PA8719401A1/es unknown
- 2007-03-20 BR BRPI0711045-6A patent/BRPI0711045A2/pt not_active IP Right Cessation
- 2007-03-20 DE DE602007011906T patent/DE602007011906D1/de active Active
- 2007-03-20 KR KR1020087025480A patent/KR20080110834A/ko not_active Ceased
- 2007-03-20 NZ NZ571326A patent/NZ571326A/en not_active IP Right Cessation
- 2007-03-20 EP EP07753547A patent/EP2001890B1/fr not_active Not-in-force
- 2007-03-20 JP JP2009501517A patent/JP5282026B2/ja not_active Expired - Fee Related
- 2007-03-20 US US12/225,285 patent/US8501755B2/en not_active Expired - Fee Related
- 2007-03-20 ES ES07753547T patent/ES2357654T3/es active Active
- 2007-03-20 RU RU2008141239/04A patent/RU2008141239A/ru not_active Application Discontinuation
- 2007-03-20 CN CN2007800178021A patent/CN101448840B/zh not_active Expired - Fee Related
-
2008
- 2008-09-11 IL IL194028A patent/IL194028A0/en unknown
- 2008-09-18 ZA ZA200808017A patent/ZA200808017B/xx unknown
- 2008-09-18 SV SV2008003032A patent/SV2008003032A/es not_active Application Discontinuation
- 2008-09-18 GT GT200800187A patent/GT200800187A/es unknown
- 2008-09-19 CR CR10304A patent/CR10304A/es not_active Application Discontinuation
- 2008-09-19 EC EC2008008749A patent/ECSP088749A/es unknown
- 2008-09-22 TN TNP2008000370A patent/TNSN08370A1/en unknown
- 2008-10-20 MA MA31320A patent/MA30351B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA30351B1 (fr) | Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation | |
| TN2009000428A1 (fr) | Derives de sulfonylamides destines au traitement d'une croissance cellulaire anormale | |
| MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
| MA31963B1 (fr) | Composes antagonistes du recepteur du glucagon, compositions contenant de tels composes et procedes d'utilisation | |
| MA30333B1 (fr) | Aminotetrahydropyranes utiles en tant qu'inhibiteurs de la dipeptidyle peptidase-iv pour le traitement ou la prevention du diabete. | |
| MA30988B1 (fr) | Composes destines a inhiber la progression mitotique | |
| TNSN07275A1 (fr) | Derives de triazole substitues, servant d'antagonistes d'ocytocine | |
| TNSN07022A1 (fr) | Derives de pyridine | |
| TNSN08445A1 (fr) | Derives de triazolopyrazine utiles comme agent anticancereux | |
| TN2009000471A1 (fr) | Composes amino-heterocycliques | |
| MA29926B1 (fr) | Derives de pyrazine | |
| MA30405B1 (fr) | Derives de 4-benzylphtalazinone substitues en 2 en tant qu'antagonistes des histamines hl et h3 | |
| MA31027B1 (fr) | INHIBITEURS DE L'ACTIVITE Akt | |
| MA32171B1 (fr) | Compose heterocyclique | |
| MA31419B1 (fr) | Derives de pyridine | |
| MA27560A1 (fr) | Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation | |
| MA34207B1 (fr) | Inhibiteurs de la pi3 kinase et/ou du mtor | |
| MA29411B1 (fr) | 1h-quinazoline -2,4-diones et leur utilisation en tant que ligands du recepteur ampa | |
| MA30916B1 (fr) | Nouveaux derives de benzamide en tant qu'antagonistes de bradykinine | |
| MA31710B1 (fr) | (carboxylalkylenephenyl)phényloxamides, procédés pour la production de ceux-ci et utilisation de ceux-ci en tant que medicament | |
| MA29480B1 (fr) | Pyrrolopyridines substitues, compositions les contenant, procede de fabrication et utilisation | |
| MA33836B1 (fr) | Compositions pharmaceutiques contenant des ligands des récepteurs sigma | |
| MA30166B1 (fr) | Imidazoles substitues et leur utilisation comme pesticides. | |
| MA35184B1 (fr) | Antagonistes de trpv4 | |
| TNSN08270A1 (fr) | Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale |